Disclosed are compounds of Formula 1,and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.所揭露內容係具有結構式1之化合物，以及其藥學上可接受之鹽類，其中G、L1、L2、R1、R2、R3與R4係於說明書中定義。此揭露內容亦相關於用於製備具有結構式1之化合物、包含它們的藥學組合物的材料和方法，以及它們用於治療涉及免疫系統與炎症的失調、疾病以及症狀之用途，其包括類風濕性關節炎、血液惡性腫瘤、類上皮癌(即癌症)以及其他須以SYK抑制作用治療之失調、疾病與症狀。
